Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2023

Genmab — April 2023

Planlagt Fastgjort Låst Flyttet Genmab
835 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #88

    New Desensitization Strategy: Daratumumab for Highly Sensitized Pediatric Heart Transplant Candidate https://www.sciencedirect.com/science/article/abs/pii/S105324982301361X

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #89

      Use of Daratumumab in Antibody Mediated Rejection in a Heart Transplant Recipient
      https://www.jhltonline.org/article/S1053-2498(23)01274-3/fulltext

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #90

        The sun is always shining with these stories on solving HT problems. Thx E L.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #91

          We reported that 4 patients with refractory acquired hemophilia A were treated with daratumumab.. All 4 patients achieved varying degrees of remission after daratumumab treatment.. Daratumumab provides a new option for the treatment of refractory acquired hemophilia with good efficacy and safety
          .

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #92

            Link Preview Image
            ScienceDirect

            favicon

            (www.sciencedirect.com)

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #93

              Det er jo herligt. Så kan mim8 og dara supplere hinanden, i tilfælde af resistens.

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #94

                Der skulle komme mim8 data til næste år.

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #95

                  … fra fase 3 studiet.

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #96

                    Det har åbenbart været kendt længe. For eksempel her: https://onlinelibrary.wiley.com/doi/10.1111/hae.14118

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #97

                      Eller her: https://hemophilianewstoday.com/news/cancer-therapy-daratumumab-can-effectively-lower-inhibitors-hemophilia-a-case-series/

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #98

                        Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-positive-topline-data

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #99

                          Do we have an estimate for Tepezza sales fy 2023?

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #100

                            i can't find anything in my notes, can't remember them giving guidance.. we may get less information once Amgen is in control..

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #101

                              small new trial for Daratumumab in Non-small Cell Lung Cancer With STK11/LKB1 Mutation (not by JNJ) https://clinicaltrials.gov/ct2/show/NCT05807048

                              1 Reply Last reply
                              0
                              • M Offline
                                M Offline
                                MarsFars
                                wrote on sidst redigeret af
                                #102

                                God aften ?

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #103

                                  Investeringspodcasten: Fokus på C25 og sidste udkald for SAS
                                  https://www.proinvestor.com/boards/111969

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #104

                                    Genmab sidst i udsendelsen.

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #105

                                      Godmorgen 🙂

                                      1 Reply Last reply
                                      0
                                      • T Offline
                                        T Offline
                                        transalp
                                        wrote on sidst redigeret af
                                        #106

                                        Go morgen.. 🙂

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          bibob
                                          wrote on sidst redigeret af
                                          #107

                                          God morgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper